{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:03:49Z","timestamp":1747170229553,"version":"3.40.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.respe.2022.09.074","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T11:31:49Z","timestamp":1666697509000},"page":"305-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimioprophylaxie antituberculeuse primaire \u00e0 l'isoniazide\u00a0:\u00a0une strat\u00e9gie d'actualit\u00e9 \u00e0 l\u2019\u00e8re du tester et traiter\u00a0;\u00a0revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-3340","authenticated-orcid":false,"given":"D.R.","family":"Moh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8917-4266","authenticated-orcid":false,"given":"A.","family":"Badj\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.N.","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"Ntakp\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.M.","family":"Kouame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ouassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Danel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Domoua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Anglaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.P.","family":"Eholi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.respe.2022.09.074_bib0001","unstructured":"World Health Organization. Global tuberculosis report 2018. 2018."},{"key":"10.1016\/j.respe.2022.09.074_bib0002","unstructured":"WHO | Guidelines on the management of latent tuberculosis infection [Internet]. WHO. [cit\u00e9 4 oct 2017]. Disponible sur: http:\/\/www.who.int\/tb\/publications\/latent-tuberculosis-infection\/en\/"},{"issue":"25","key":"10.1016\/j.respe.2022.09.074_bib0003","doi-asserted-by":"crossref","first-page":"723\u20116","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 5","key":"10.1016\/j.respe.2022.09.074_bib0004","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/01.aids.0000391023.03037.1f","article-title":"Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions","volume":"24","author":"Getahun","year":"2010","journal-title":"AIDS"},{"issue":"9944","key":"10.1016\/j.respe.2022.09.074_bib0005","doi-asserted-by":"crossref","first-page":"682\u201190","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial","volume":"384","author":"Rangaka","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.respe.2022.09.074_bib0006","first-page":"808\u201122","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"issue":"9105","key":"10.1016\/j.respe.2022.09.074_bib0007","first-page":"786\u201192","article-title":"Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection","volume":"351","author":"Halsey","year":"1998","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.respe.2022.09.074_bib0008","doi-asserted-by":"crossref","first-page":"1445\u201150","DOI":"10.1001\/jama.283.11.1445","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.respe.2022.09.074_bib0009","first-page":"305\u20117","article-title":"No effect of isoniazid prophylaxis for purified protein derivative-negative Hiv-infected adults living in a country with endemic tuberculosis: results of a randomized trial","volume":"28","author":"Fitzgerald","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"22","key":"10.1016\/j.respe.2022.09.074_bib0010","doi-asserted-by":"crossref","first-page":"2719\u201125","DOI":"10.1001\/jama.293.22.2719","article-title":"Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-Infected Men in South Africa: a novel randomized incremental recruitment study","volume":"293","author":"Grant","year":"2005","journal-title":"JAMA"},{"issue":"9777","key":"10.1016\/j.respe.2022.09.074_bib0011","first-page":"1588\u201198","article-title":"6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"Samandari","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"8866","key":"10.1016\/j.respe.2022.09.074_bib0012","doi-asserted-by":"crossref","first-page":"268\u201172","DOI":"10.1016\/0140-6736(93)91817-6","article-title":"Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection","volume":"342","author":"Pape","year":"1993","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.respe.2022.09.074_bib0013","doi-asserted-by":"crossref","first-page":"315\u201120","DOI":"10.1056\/NEJM199707313370505","article-title":"A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS","volume":"337","author":"Gordin","year":"1997","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.respe.2022.09.074_bib0014","doi-asserted-by":"crossref","first-page":"801\u20118","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.respe.2022.09.074_bib0015","doi-asserted-by":"crossref","first-page":"875\u201182","DOI":"10.1097\/00002030-199707000-00006","article-title":"Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial","volume":"11","author":"Hawken","year":"1997","journal-title":"AIDS Lond Engl"},{"issue":"18","key":"10.1016\/j.respe.2022.09.074_bib0016","doi-asserted-by":"crossref","first-page":"2447\u201157","DOI":"10.1097\/00002030-199818000-00014","article-title":"Twice weekly tuberculosis preventive therapy in HIV infection in Zambia","volume":"12","author":"Mwinga","year":"1998","journal-title":"AIDS Lond Engl"},{"issue":"10","key":"10.1016\/j.respe.2022.09.074_bib0017","first-page":"1114\u201120","article-title":"Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease","volume":"11","author":"Mohammed","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.respe.2022.09.074_bib0018","doi-asserted-by":"crossref","first-page":"11\u201120","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.respe.2022.09.074_bib0019","doi-asserted-by":"crossref","first-page":"e47400","DOI":"10.1371\/journal.pone.0047400","article-title":"Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial","volume":"7","author":"Swaminathan","year":"2012","journal-title":"PloS One"},{"issue":"10024","key":"10.1016\/j.respe.2022.09.074_bib0020","doi-asserted-by":"crossref","first-page":"1198\u2011209","DOI":"10.1016\/S0140-6736(16)00546-8","article-title":"Empiric tuberculosis therapy versus isoniazid in advanced HIV-infected adult outpatients initiating antiretroviral therapy: a multi-country randomized controlled trial","volume":"387","author":"Hosseinipour","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.respe.2022.09.074_bib0021","doi-asserted-by":"crossref","first-page":"233\u201145","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa","volume":"377","author":"Hakim","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.respe.2022.09.074_bib0022","doi-asserted-by":"crossref","first-page":"2155\u201166","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.respe.2022.09.074_bib0023","doi-asserted-by":"crossref","unstructured":"Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in Hiv-infected adults. AIDS. 15(16):2137\u201147.","DOI":"10.1097\/00002030-200111090-00009"},{"key":"10.1016\/j.respe.2022.09.074_bib0024","doi-asserted-by":"crossref","unstructured":"Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Jdh P, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of Hiv-infected Zambian adults. AIDS. 15(2):215\u201122.","DOI":"10.1097\/00002030-200101260-00011"},{"issue":"10","key":"10.1016\/j.respe.2022.09.074_bib0025","doi-asserted-by":"crossref","first-page":"1607\u201115","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine plus isoniazid for treatment of M. tuberculosis Infection in HIV Co-infected Persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS Lond Engl"},{"issue":"1","key":"10.1016\/j.respe.2022.09.074_bib0026","doi-asserted-by":"crossref","first-page":"e8\u201115","DOI":"10.1016\/S2352-3018(20)30299-X","article-title":"Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data","volume":"8","author":"Ross","year":"2021","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.respe.2022.09.074_bib0027","doi-asserted-by":"crossref","first-page":"e137\u201150","DOI":"10.1016\/S2352-3018(15)00005-3","article-title":"Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis","volume":"2","author":"Suthar","year":"2015","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.respe.2022.09.074_bib0028","doi-asserted-by":"crossref","first-page":"e1080\u20119","DOI":"10.1016\/S2214-109X(17)30372-8","article-title":"Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial","volume":"5","author":"Badje","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.respe.2022.09.074_bib0029","doi-asserted-by":"crossref","first-page":"117\u201128","DOI":"10.1016\/0736-4679(84)90331-7","article-title":"Acquired immune deficiency syndrome","volume":"2","author":"Seger","year":"1984","journal-title":"J Emerg Med"},{"issue":"1","key":"10.1016\/j.respe.2022.09.074_bib0030","doi-asserted-by":"crossref","first-page":"1\u201121","DOI":"10.1093\/oxfordjournals.epirev.a036277","article-title":"Epidemiology of the acquired immunodeficiency syndrome (AIDS)","volume":"7","author":"Peterman","year":"1985","journal-title":"Epidemiol Rev"},{"issue":"2","key":"10.1016\/j.respe.2022.09.074_bib0031","doi-asserted-by":"crossref","first-page":"130\u20116","DOI":"10.1001\/jama.279.2.130","article-title":"The Cost-effectiveness of preventing AIDS-Related opportunistic infections","volume":"279","author":"Freedberg","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.respe.2022.09.074_bib0032","doi-asserted-by":"crossref","first-page":"714\u201123","DOI":"10.1093\/cid\/cir898","article-title":"AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire","volume":"54","author":"Anglaret","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.respe.2022.09.074_bib0033","unstructured":"WHO | Global tuberculosis report 2016 [Internet]. WHO. [cit\u00e9 4 oct 2017]. Disponible sur: http:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"issue":"Suppl 2","key":"10.1016\/j.respe.2022.09.074_bib0034","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1093\/clinids\/11.Supplement_2.S347","article-title":"Present status of chemotherapy for tuberculosis","volume":"11","author":"Grosset","year":"1989","journal-title":"Rev Infect Dis"},{"issue":"2, Part 2","key":"10.1016\/j.respe.2022.09.074_bib0035","doi-asserted-by":"crossref","first-page":"e13\u201121","DOI":"10.1016\/j.lpm.2017.01.015","article-title":"Tuberculosis elimination and the challenge of latent tuberculosis","volume":"46","author":"Matteelli","year":"2017","journal-title":"Presse M\u00e9d"},{"issue":"5","key":"10.1016\/j.respe.2022.09.074_bib0036","doi-asserted-by":"crossref","first-page":"1327\u201130","DOI":"10.1183\/13993003.00449-2016","article-title":"Advancing global programmatic management of latent tuberculosis infection for at risk populations","volume":"47","author":"Getahun","year":"2016","journal-title":"Eur Respir J"},{"issue":"suppl_2","key":"10.1016\/j.respe.2022.09.074_bib0037","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1093\/cid\/cix1139","article-title":"Managing Advanced HIV Disease in a Public Health Approach","volume":"66","author":"Ford","year":"2018","journal-title":"Clin Infect Dis"},{"year":"2020","series-title":"WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment [Internet]","key":"10.1016\/j.respe.2022.09.074_bib0038"},{"issue":"11","key":"10.1016\/j.respe.2022.09.074_bib0039","doi-asserted-by":"crossref","first-page":"1001\u201111","DOI":"10.1056\/NEJMoa1806808","article-title":"One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039876202200832X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039876202200832X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T01:37:16Z","timestamp":1686101836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S039876202200832X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S039876202200832X"],"URL":"https:\/\/doi.org\/10.1016\/j.respe.2022.09.074","relation":{},"ISSN":["0398-7620"],"issn-type":[{"type":"print","value":"0398-7620"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimioprophylaxie antituberculeuse primaire \u00e0 l'isoniazide\u00a0:\u00a0une strat\u00e9gie d'actualit\u00e9 \u00e0 l\u2019\u00e8re du tester et traiter\u00a0;\u00a0revue de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.respe.2022.09.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}